Private Ltd Gic Sells 1,976,618 Shares of Medline (NASDAQ:MDLN) Stock

Key Points

• Private Ltd Gic sold 1,976,618 Medline shares for approximately $70.4 million at an average price of $35.60, reducing its position by 7.26% to 25.26 million shares. It also sold an additional 271,994 shares the following day.
• Medline reported quarterly EPS of $0.50, beating the $0.32 consensus estimate, on revenue of about $7.68 billion. The company raised its 2026 organic-sales growth outlook to 9%–10% but lowered adjusted EBITDA guidance to $3.3 billion–$3.4 billion.
• Shares recently traded around $35.23, while analysts maintained an overall “Moderate Buy” rating with a consensus price target of $48.50, despite several firms lowering their targets.

Medline (NASDAQ:MDLN - Get Free Report) major shareholder Private Ltd Gic sold 1,976,618 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $35.60, for a total transaction of $70,367,600.80. Following the sale, the insider directly owned 25,264,760 shares of the company's stock, valued at $899,425,456. The trade was a 7.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

Private Ltd Gic also recently made the following trade(s):

• On Thursday, August 6th, Private Ltd Gic sold 271,994 shares of Medline stock. The shares were sold at an average price of $35.33, for a total value of $9,609,548.02.

Medline Stock Up 2.1%

NASDAQ MDLN traded up $0.72 during trading on Friday, hitting $35.23. The company's stock had a trading volume of 8,293,636 shares, compared to its average volume of 7,380,132. Medline has a fifty-two week low of $32.81 and a fifty-two week high of $50.88. The company has a market cap of $46.28 billion and a PE ratio of 110.09. The company has a debt-to-equity ratio of 0.65, a current ratio of 4.41 and a quick ratio of 2.51. The business's 50 day simple moving average is $38.24 and its 200-day simple moving average is $41.77.

Medline (NASDAQ:MDLN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.32 by $0.18. The company had revenue of $7.68 billion during the quarter. On average, equities analysts anticipate that Medline will post 1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MDLN. Truist Financial lowered their price target on Medline from $56.00 to $47.00 and set a "buy" rating for the company in a research report on Thursday. Sanford C. Bernstein decreased their target price on Medline from $56.00 to $54.00 and set an "outperform" rating for the company in a report on Thursday, May 7th. Barclays dropped their target price on Medline from $50.00 to $45.00 and set an "overweight" rating on the stock in a research report on Monday, June 1st. Royal Bank Of Canada reduced their price target on shares of Medline from $53.00 to $46.00 and set an "outperform" rating for the company in a research report on Thursday. Finally, William Blair restated an "outperform" rating on shares of Medline in a research report on Thursday, June 4th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Medline has an average rating of "Moderate Buy" and a consensus target price of $48.50.

Trending Headlines about Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported second-quarter earnings of $0.50 per share, exceeding the $0.32 analyst consensus, while revenue reached $7.69 billion. The company also raised its 2026 organic-sales growth forecast to 9%–10%, signaling continued demand for its medical products. Medline Q2 Earnings Snapshot Medline Raises 2026 Organic Sales Outlook
• Positive Sentiment: BTIG reiterated a Buy rating and $55 price target, citing robust growth and viewing current headwinds as transitory. At that target, the shares would have substantial potential upside from recent trading levels. BTIG Medline Rating
• Neutral Sentiment: Truist lowered its price target from $56 to $47, and Stifel reduced its target from $50 to $45, but both firms maintained Buy ratings. The target cuts reflect increased caution, while the continued recommendations indicate analysts still see meaningful long-term upside. Truist Price Target Update Stifel Price Target Update
• Negative Sentiment: Medline lowered its 2026 adjusted EBITDA forecast to $3.3 billion–$3.4 billion despite the sales outlook increase. The weaker profit guidance has weighed on the stock because it suggests margin pressure or higher costs and offsets the quarterly earnings beat. Medline Falls After EBITDA Outlook Cut
• Negative Sentiment: Several law firms, including Kaplan Fox and Kessler Topaz, announced investigations into potential securities-law violations involving Medline. The actions follow an FDA warning letter reportedly identifying significant violations. These announcements create legal, regulatory and reputational risks, although the investigations do not establish wrongdoing. Kaplan Fox Medline Investigation Kessler Topaz Medline Investigation

Institutional Trading of Medline

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp purchased a new position in shares of Medline during the 2nd quarter valued at approximately $40,430,000. E. Ohman J or Asset Management AB acquired a new position in Medline during the second quarter worth $508,000. GAMMA Investing LLC raised its position in Medline by 68.3% during the second quarter. GAMMA Investing LLC now owns 626 shares of the company's stock worth $25,000 after acquiring an additional 254 shares during the period. Parallel Advisors LLC lifted its holdings in Medline by 1,073.3% during the first quarter. Parallel Advisors LLC now owns 5,280 shares of the company's stock valued at $235,000 after purchasing an additional 4,830 shares in the last quarter. Finally, CTC Alternative Strategies Ltd. acquired a new stake in shares of Medline in the first quarter valued at about $1,048,000.

About Medline

Medline NASDAQ: MDLN is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source